Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials

Schilke ED, Remoli G, Funelli E, Galimberti M, Fusco ML, Cereda D, Balducci C, Frigo M, Cavaletti G. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials. Neurol Sci. 2024 May;45(5):1931-1944. doi: 10.1007/s10072-023-07228-3. Epub 2023 Dec 20. PMID: 38117403; PMCID: PMC11021285.

https://pubmed.ncbi.nlm.nih.gov/38117403/

← Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants
Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection →